IRIS
DELLA PORTA, MATTEO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.170
AS - Asia 4.547
EU - Europa 1.464
SA - Sud America 682
AF - Africa 222
Continente sconosciuto - Info sul continente non disponibili 137
OC - Oceania 15
Totale 15.237
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.964
SG - Singapore 2.761
CN - Cina 864
BR - Brasile 555
VN - Vietnam 382
IT - Italia 341
FI - Finlandia 283
IE - Irlanda 202
NG - Nigeria 160
HK - Hong Kong 144
CA - Canada 124
DE - Germania 118
FR - Francia 116
GB - Regno Unito 92
IN - India 86
NL - Olanda 76
SE - Svezia 56
JP - Giappone 48
MX - Messico 47
TR - Turchia 43
AR - Argentina 40
BD - Bangladesh 35
IQ - Iraq 34
ES - Italia 31
PL - Polonia 26
ZA - Sudafrica 22
RU - Federazione Russa 21
BE - Belgio 20
CL - Cile 16
EC - Ecuador 16
PK - Pakistan 16
VE - Venezuela 15
CO - Colombia 14
UA - Ucraina 14
SA - Arabia Saudita 13
ID - Indonesia 12
JM - Giamaica 12
PY - Paraguay 12
UZ - Uzbekistan 12
AU - Australia 11
JO - Giordania 11
PH - Filippine 11
IR - Iran 10
KR - Corea 9
MY - Malesia 9
GR - Grecia 8
KE - Kenya 8
AE - Emirati Arabi Uniti 7
AT - Austria 7
CH - Svizzera 7
MA - Marocco 7
PE - Perù 7
CZ - Repubblica Ceca 6
NP - Nepal 6
BG - Bulgaria 5
CR - Costa Rica 5
KZ - Kazakistan 5
LT - Lituania 5
TH - Thailandia 5
TN - Tunisia 5
DK - Danimarca 4
EG - Egitto 4
IL - Israele 4
NZ - Nuova Zelanda 4
OM - Oman 4
AL - Albania 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
KH - Cambogia 3
NO - Norvegia 3
PA - Panama 3
RO - Romania 3
UY - Uruguay 3
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
CI - Costa d'Avorio 2
EU - Europa 2
GT - Guatemala 2
GY - Guiana 2
HN - Honduras 2
IS - Islanda 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MR - Mauritania 2
NI - Nicaragua 2
PT - Portogallo 2
SN - Senegal 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BS - Bahamas 1
DZ - Algeria 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
Totale 15.089
Salva come PNG Salva come JPEG
Città #
Singapore 1.342
Wilmington 1.029
Chandler 954
Ashburn 501
The Dalles 411
Shanghai 370
San Mateo 356
San Jose 349
Helsinki 282
Ann Arbor 246
Council Bluffs 237
Dallas 227
Dublin 201
Boardman 186
Beijing 182
Princeton 166
Leawood 165
Benin City 159
Lawrence 159
New York 154
Milan 143
Hong Kong 130
Woodbridge 121
Ho Chi Minh City 116
Santa Clara 105
Fairfield 101
Hanoi 101
Los Angeles 100
Paris 93
Amsterdam 65
São Paulo 58
Rome 56
Toronto 55
Buffalo 47
Houston 47
Phoenix 46
Seattle 42
Tokyo 41
London 37
Charlotte 27
Orem 26
Haiphong 24
Montreal 24
Cambridge 23
Falls Church 23
Norwalk 23
San Diego 23
San Francisco 21
Brussels 20
Warsaw 20
Boston 19
Brooklyn 19
Columbus 19
Kocaeli 18
Redwood City 17
Chicago 16
Da Nang 16
Redmond 16
Rio de Janeiro 16
Monmouth Junction 15
Belo Horizonte 14
Chennai 14
Mexico City 14
Stockholm 14
Falkenstein 12
Baghdad 11
Figino 11
Kingston 11
Nanjing 11
Tashkent 11
Atlanta 10
Brasília 10
Curitiba 10
Hillsboro 10
Miami 10
Mumbai 10
Pune 10
Turin 10
Amman 9
Frankfurt am Main 9
Guangzhou 9
Johannesburg 9
Manchester 9
Naples 9
Tappahannock 9
Assago 8
Athens 8
Hangzhou 8
New Delhi 8
Philadelphia 8
Phủ Lý 8
Richmond 8
Washington 8
Guarulhos 7
Newark 7
Pittsburgh 7
Quito 7
Vancouver 7
Ankara 6
Biên Hòa 6
Totale 9.982
Salva come PNG Salva come JPEG
Nome #
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 211
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun. 2015 Jan 9;6:5901. 140
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group 123
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 123
Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 117
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 117
Costimulatory molecules and immune checkpoints are differentially expressed on different subsets of dendritic cells 117
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 116
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006 Nov 1;107(9):2206-11. PubMed PMID: 16998940. 113
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years 113
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system (IPSS-R) 112
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 110
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 109
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 105
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data. 105
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 105
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML 105
CD34 and CD2 expression in acute promyelocytic leukemia. 104
Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. 99
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 99
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes 99
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 98
Leukemic transformation of polycythemia vera: a single center study of 23 patients 97
Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. 96
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) 95
Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications. 92
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 92
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 91
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. 91
Classification and prognostic evaluation of myelodysplastic syndromes 90
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? 90
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 90
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. 89
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 89
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival 89
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 89
Prognosis of secondary acute myeloid leukemia 88
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) 88
Multicentre validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study. 88
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 88
Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL). 88
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 88
27P * Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells 88
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 87
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. 86
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. 86
Importance of classical morphology in the diagnosis of myelodysplastic syndrome. 86
An unusual clinical presentation of multiple myeloma with involvement of the oro-pharynx. 85
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. 85
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 85
Sequence variations in mitochondrial ferritin: distribution in healthy controls and different types of patients. 84
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 84
Differentiation of follicular dendritic sarcoma cells into functional myeloid-dendritic cell-like elements. 84
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 84
Dendritic cells in acute promyelocytic leukaemia. 83
Clinical and biological implications of driver mutations in myelodysplastic syndromes 83
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 83
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 83
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome 83
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 82
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 82
Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 82
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. 82
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. 81
Myelodysplastic syndromes and bone marrow microenvironment. 81
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 81
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 80
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 80
Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. 80
Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells. 79
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 79
Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. 79
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 79
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 79
Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. 79
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome 79
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study 77
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 77
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 77
Simian virus 40 and lymphoproliferative disorder. 77
Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis. 76
Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia 76
rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. 76
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 76
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients 76
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 76
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. 76
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 76
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 76
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS 76
Prognostic models in myelodysplastic syndromes 75
The Genetics of Myelodysplastic Syndromes: Clinical Relevance 74
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 74
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 74
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 74
Opportunities and Challenges of Synthetic Data Generation in Oncology 73
Novel trial designs for high-risk myelodysplastic syndromes. 73
Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients 73
High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene. 72
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 72
Totale 8.953
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022989 0 12 24 213 23 26 29 132 105 70 323 32
2022/20232.634 374 85 210 325 252 237 5 234 493 210 176 33
2023/20241.356 121 178 278 47 27 115 57 149 20 46 167 151
2024/20252.000 58 51 24 42 22 275 77 238 255 511 234 213
2025/20265.468 880 275 253 433 179 212 1.706 309 289 352 231 349
2026/2027880 384 496 0 0 0 0 0 0 0 0 0 0
Totale 15.237